XML 14 R23.htm IDEA: XBRL DOCUMENT v2.3.0.15
Related Party Transactions
9 Months Ended
Sep. 30, 2011
RELATED PARTY TRANSACTION [Abstract] 
Related Party Transactions Disclosure [Text Block]
RELATED PARTY TRANSACTIONS
The table below presents the transactions between the Company and Watson.
 
Nine Months Ended September 30,
 
Three Months Ended September 30,
 
2011
 
2010
 
2011
 
2010
REVENUES
 

 
 

 
 
 
 
Net product revenues
$
1,513,296

 
$
581,104

 
$
574,956

 
$
581,104

Royalties
1,845,154

 
450,000

 
702,336

 
450,000

Amortization of deferred revenue
16,974,383

 
8,487,192

 

 
8,487,192

Milestone payment
5,000,000

 

 

 

Other revenue
21,974,383

 
8,487,192

 

 
8,487,192

 
 
 
 
 
 
 
 
Total net revenues
$
25,332,833

 
$
9,518,296

 
$
1,277,292

 
$
9,518,296

COST OF PRODUCT REVENUES
 

 
 

 
 
 
 
Cost of product revenues
1,453,720

 
528,473

 
636,232

 
528,473

Gross profit
$
23,879,113

 
$
8,989,823

 
$
641,060

 
$
8,989,823

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Accounts receivable
$
932,052

 
$
533,445

 
 
 
 
The Company has exceeded the cap of $7.0 million by $2.7 million for research and development spending on the PREGNANT study and related Preterm Birth NDA pursuant to the Watson Transactions and has recorded this amount as a reduction of research and development expenses. Watson has paid the Company for $2.4 million of these excess amounts and has been invoiced for the remaining $0.3 million.